Skip to content

Autologous Prefabrication of Body Surface Tissues/ Organs(e.g. Joint)

Phase 1/2 Study of Autologous Tissues/Body Surface Organs Prefabrication in Tissue Reconstruction

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02595047
Enrollment
1
Registered
2015-11-03
Start date
2013-01-31
Completion date
2016-12-31
Last updated
2015-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intentional Self Harm by Other Specified Means, Soft Tissue Infections

Keywords

Self-regeneration, in vivo tissue prefabrication,

Brief summary

The purpose of this study is to observe the feasibility and its application of autologous prefabrication for body surface tissues/oranges

Detailed description

In the field of tissue regeneration techniques, the in vitro processes and other exogenous factors still have many uncertainties. These uncertainties have hampered road to the clinical application. As the importance of in vivo environment has aroused more awareness, the investigators validated the hypothesis that the feasibility of self-regeneration prefabricated unaided by any in vitro culture process or exogenous elements.

Interventions

PROCEDUREtissue/ organ prefabrication

tissue/ organ is prefabricated in vivo independent of exogenous factors for replacement/ reconstruction purposes

Sponsors

Shanghai Jiao Tong University School of Medicine
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
5 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* With body surface tissue or organ defects (e.g., ear, nose, bone and joint) requiring reconstruction.

Exclusion criteria

* evidence of infection, ischemia, ulcer or other pathological changes within the prefabricated area which defined as not suitable for tissues regeneration * history of delayed healing, radiational therapy; * significant renal, cardiovascular, hepatic and psychiatric diseases; * significant medical diseases or infection (including but not limited to the carrier of hepatitis B virus or HIV); * BMI \>30; * history of any hematological disease, including leukopenia, thrombocytopenia, or thrombocytosis; * Evidence of malignant diseases * unwillingness to participate.

Design outcomes

Primary

MeasureTime frameDescription
Occurence of major adverse eventsthrough study completion 12 months after prefabricationIncluding infection, necrosis, resorption

Secondary

MeasureTime frameDescription
Feasibility of self-prefabrication3, 6, and 12 months after prefabricationTo observe the regeneration changes of prefabricated neo-tissue by histology (staining) and biomechanical analysis (bone density, Young's modulus)

Other

MeasureTime frameDescription
survival of prefabricated tissue after grafting3, 6, 12, and 36 months after graftingAssessed by radiologic imaging (CT, MRT)
biomechanical function of prefabricated tissue after grafting3, 6, 12, and 36 months after graftingAssessed by total range of motion (degree)

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026